Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderson, S.
Right arrow Articles by Mladenovic, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderson, S.
Right arrow Articles by Mladenovic, J
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion

SM Anderson and J Mladenovic

Department of Pathology, Colorado Health Science Center, Denver 80262, USA.

Expression of either the BCR-ABL or the v-abl oncogene in the factor- dependent murine myeloid cell line FDCP-1 results in growth factor independence. Studies with temperature-sensitive mutants of v-abl show that this growth factor independence is oncogene dependent. Likewise, cells expressing a kinase inactive mutant of BCR-ABL did not grow in the absence of interleukin-3 (IL-3). Conditioned media from cells expressing either v-abl or BCR-ABL contained growth factor(s) capable of stimulating the proliferation of uninfected FDCP-1 cells. Based on enzyme-linked immunosorbent assay studies and antibody neutralization studies, the major growth factor present in these conditioned media is IL-3. Because of the importance of SH2 domains in regulating substrate interactions, we examined the ability of SH2 deletion mutants in BCR- ABL to induce growth factor independence. Cells expressing a mutant of BCR-ABL lacking the SH2 domain were growth factor independent; however, they did not secrete growth factors. This finding suggests that while IL-3 produced by cells infected with BCR-ABL may contribute to autocrine or paracrine growth factor independence, expression of an activated tyrosine kinase alone may be able to induce growth factor independence. Furthermore, the secretion of cytokines maybe correlated with a specific region of the BCR-ABL oncogene, suggesting that activation (phosphorylation) of specific substrates may be critical for transcriptional activation of cytokine genes.

Volume 87, Issue 1, pp. 238-244, 01/01/1996
Copyright © 1996 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
S. Wong, J. McLaughlin, D. Cheng, and O. N. Witte
Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors
Blood, May 15, 2003; 101(10): 4088 - 4097.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. M. Golas, K. Arndt, C. Etienne, J. Lucas, D. Nardin, J. Gibbons, P. Frost, F. Ye, D. H. Boschelli, and F. Boschelli
SKI-606, a 4-Anilino-3-quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice
Cancer Res., January 15, 2003; 63(2): 375 - 381.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
X. Jiang, E. Ng, C. Yip, W. Eisterer, Y. Chalandon, M. Stuible, A. Eaves, and C. J. Eaves
Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo
Blood, November 15, 2002; 100(10): 3731 - 3740.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Laurent, M. Talpaz, H. Kantarjian, and R. Kurzrock
The BCR Gene and Philadelphia Chromosome-positive Leukemogenesis
Cancer Res., March 1, 2001; 61(6): 2343 - 2355.
[Full Text]


Home page
BloodHome page
M. H. Tomasson, I. R. Williams, S. Li, J. Kutok, D. Cain, S. Gillessen, G. Dranoff, R. A. Van Etten, and D. G. Gilliland
Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3
Blood, March 1, 2001; 97(5): 1435 - 1441.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. L. Holyoake, X. Jiang, H. G. Jorgensen, S. Graham, M. J. Alcorn, C. Laird, A. C. Eaves, and C. J. Eaves
Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3
Blood, February 1, 2001; 97(3): 720 - 728.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Roumiantsev, I. E. de Aos, L. Varticovski, R. L. Ilaria, and R. A. Van Etten
The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase
Blood, January 1, 2001; 97(1): 4 - 13.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
X. Zhang, R. Wong, S. X. Hao, W. S. Pear, and R. Ren
The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype
Blood, January 1, 2001; 97(1): 277 - 287.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. Di Bacco, K. Keeshan, S. L. McKenna, and T. G. Cotter
Molecular Abnormalities in Chronic Myeloid Leukemia: Deregulation of Cell Growth and Apoptosis
Oncologist, October 1, 2000; 5(5): 405 - 415.
[Abstract] [Full Text]


Home page
BloodHome page
T. Jonuleit, H. van der Kuip, C. Miething, H. Michels, M. Hallek, J. Duyster, and W. E. Aulitzky
Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines
Blood, September 1, 2000; 96(5): 1933 - 1939.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
X. Jiang, A. Lopez, T. Holyoake, A. Eaves, and C. Eaves
Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia
PNAS, October 26, 1999; 96(22): 12804 - 12809.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
M. Nieborowska-Skorska, M. A. Wasik, A. Slupianek, P. Salomoni, T. Kitamura, B. Calabretta, and T. Skorski
Signal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis
J. Exp. Med., April 19, 1999; 189(8): 1229 - 1242.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
X. Zhang and R. Ren
Bcr-Abl Efficiently Induces a Myeloproliferative Disease and Production of Excess Interleukin-3 and Granulocyte-Macrophage Colony-Stimulating Factor in Mice: A Novel Model for Chronic Myelogenous Leukemia
Blood, November 15, 1998; 92(10): 3829 - 3840.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Hamilton, K. M. Miller, K. M. Helm, W. Y. Langdon, and S. M. Anderson
Suppression of Apoptosis Induced by Growth Factor Withdrawal by an Oncogenic Form of c-Cbl
J. Biol. Chem., March 16, 2001; 276(12): 9028 - 9037.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1996 by American Society of Hematology         Online ISSN: 1528-0020